Nasopharyngeal Carcinoma Treatment Market (2021- 2027) | Global Industry Size, Share, Upcoming Trends, Business Growth, Competitive Landscape and Forecast to 2027
SEATTLE, April 09, 2021, (PHARMIWEB) — Global Nasopharyngeal Carcinoma Treatment Market
Nasopharyngeal carcinoma is a rare cancer, affecting the part of throat that connects the nose and the mouth, known as pharynx. Nasopharyngeal carcinoma are of three types, based on cell appearance under microscope. These types include keratinizing squamous cell carcinoma, non-keratinizing differentiated carcinoma, and undifferentiated carcinoma. The early-stage symptoms of nasopharyngeal carcinoma are bleeding nose, blockage and stuffiness in nose, persistent ear infection, hearing difficulties, and sore throat whereas, late stage symptoms includes weight loss, facial pain, and bulging eye.
A sample of this report is available upon request @ https://www.coherentmarketinsights.com/insight/request-sample/2015
Nasopharyngeal cancers are usually diagnosed by EBV antibody test, X-ray, ultrasound, endoscopy, biopsy, CT scan, MRI, PET scan or PET-CT scan. Nasopharyngeal treatment includes use of radiation therapy or chemotherapy, however, surgery is done in very rare cases. According to National Center for Biotechnology Information 2016, incidence of nasopharyngeal cancer differs according to the geography, where 81% of new cases are observed in Asia, 9% in Africa and only 10% are diagnosed in rest of the world. The global nasopharyngeal carcinoma treatment market is expected to be driven by high incidence rate of the cancer in Asian countries and increasing research and development studies by research organization and universities for treatment of this cancer.
Global Nasopharyngeal Carcinoma Treatment Market Dynamics
Increasing incidence of nasopharyngeal cancer is expected to drive the growth of the global nasopharyngeal carcinoma treatment market in the forecast period (2018-2026. According to the American Cancer Society, 2016, incidence of nasopharyngeal cancer is 1 in 100,000 each year, globally. The report further says that there would be about 3,200 cases of nasopharyngeal cancer in the U.S. in the near future. According to the Canadian Cancer Society’s statistics 2013, 240 Canadians are diagnosed with nasopharyngeal cancer every year, whereas, 102 die due to nasopharyngeal cancer every year. According to NHS UK, in the U.K., about 240 people are diagnosed with nasopharyngeal cancer each year.
In 2018, the World Cancer Research reported that nasopharyngeal cancer is about three times more common in men as compared to women. According to an article released in the Chinese Journal of Cancer, 21,320 people died due to nasopharyngeal cancer in China in 2013, which attributes to 1.14% of all new cancer cases and 0.96% of all cancer-related deaths. Moreover, increasing exposure to smoking tobacco, Epstein-Barr virus, wood dust, and others is expected to further propel the growth of the global nasopharyngeal cancer treatment market.
Research studies conducted by researchers and healthcare providers, to develop better treatment option, is further expected to propel growth of the nasopharyngeal carcinoma treatment market. Taiho Pharmaceutical has new chemotherapy drugs such as S-1 and valproic acid which shows promising potential to treat head and neck cancer.
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2015
On other hand, the popularity of targeted therapies such as tyrosine kinase inhibitors (dacomitinib, gefitinib, afatinib, erlotinib and lapatinib), phosphoinositide 3-kinase inhibitors (PX-866 and buparlisib), monoclonal antibodies (panitumumab), and mTOR inhibitors (everolimus and temsirolimus) is increasing significantly for the treatment of cancers. For instance, Cetuximab also known as Erbitux, a monoclonal antibody that acts as an epidermal growth factor receptor (EGFR) inhibitor, is been in trial for treating squamous cell nasopharyngeal cancer. Furthermore, nimotuzumab is another EGFR inhibitor with chemotherapy to treat locally advanced nasopharyngeal cancer.
Moreover, antitumor activity of nivolumab (Opdivo) is evaluated for recurrent and metastatic nasopharyngeal carcinoma by Mayo Clinic, which was in phase II clinical trials as per article published in Journal of Clinical Oncology, March 2018.
Global Nasopharyngeal Carcinoma Treatment Market – Regional Analysis
North America is expected to be dominant market over the forecast period, owing to increasing research and developmental activities by key market players in the region to develop better treatment.
However, Asia Pacific is expected to be fastest growing hypo-pharyngeal cancer treatment market, due to increasing incidence of nasopharyngeal carcinoma in the region. According to the Canadian Cancer Society, the risk factor for developing cancer is higher in Southeast Asian or Chinese ancestry, particularly Cantonese ancestry. According to Union for International Cancer Control 2014, APAC countries like Southern China and Southeast Asia, the annual age-standardized incidence rates are as high as 20 to 30 cases per 100,000 population in men and 8 to 15 cases per 100,000 population in women in comparison to the U.S., where it is less than 1 per 100,000. As per the article published in the World Cancer Research Journal, in 2012, there were 42,100 cases of nasopharyngeal cancer detected in China, 13,084 cases in Indonesia, 4,931 cases in Vietnam, 3,947 in India, and 2,030 in Malaysia.
Global Nasopharyngeal Carcinoma Treatment Market – Key Competitors
The key players operating in the global nasopharyngeal carcinoma treatment market are Pfizer Inc., Sanofi, Merck & Co., Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., and Fresenius SE & Co. KGaA.
By Drug Type,
By Distribution Channel,
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire